What AI agents think about this news
Panelists agree that Leidos (LDOS) faces challenges, with revenue growth stalling and underperformance against peers like CACI. However, opinions differ on the cause and potential resolution.
Risk: Competitive deterioration and potential execution issues in the defense IT segment, as highlighted by Anthropic and Grok.
Opportunity: Potential re-rating catalyst if LDOS can demonstrate organic revenue growth acceleration, as suggested by OpenAI.
Reston, Virginia-based Leidos Holdings, Inc. (LDOS) provides services and solutions in the defense, intelligence, engineering, civil, and health markets. With a market cap of $21.2 billion, the company provides scientific, engineering, systems integration, and technical services and solutions.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and LDOS perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the information technology services industry. LDOS’ strengths include diversification, strong brand equity, financial resilience, tech innovation, and robust supply chain. Its adaptive strategy keeps it ahead in government and enterprise markets.
More News from Barchart
-
What Options Traders Expect from Micron Stock After Earnings on March 18
-
This Dividend King With a 54-Year Dividend Streak Is Down 13% YTD. Time to Buy the Dip?
-
Stocks Set to Open Higher as Bond Yields Fall, Fed Meeting and Middle East Conflict in Focus
Despite its notable strength, LDOS slipped 18.6% from its 52-week high of $205.77, achieved on Nov. 4, 2025. Over the past three months, LDOS stock declined 8.1%, underperforming the S&P 500 Index’s ($SPX) 1.5% decline during the same time frame.
Shares of LDOS fell 8.3% on a six-month basis, underperforming SPX’s six-month gains of 1.4%. However, in the longer term, the stock climbed 24.5% over the past 52 weeks, outperforming SPX’s 18.8% returns over the last year.
To confirm the bearish trend, LDOS is trading below its 50-day and 200-day moving averages since early February.
On Feb. 17, LDOS shares closed down more than 8% after reporting its Q4 results. Its adjusted EPS of $2.76 beat Wall Street expectations of $2.57. The company’s revenue was $4.2 billion, falling short of Wall Street forecasts of $4.3 billion. LDOS expects full-year adjusted EPS in the range of $12.05 to $12.45, and revenue in the range of $17.5 billion to $17.9 billion.
In the competitive arena of information technology services, CACI International Inc (CACI) has taken the lead over LDOS, showing resilience with a 62.2% uptick over the past 52 weeks and 23.2% gains over the past six months.
Wall Street analysts are reasonably bullish on LDOS’ prospects. The stock has a consensus “Moderate Buy” rating from the 16 analysts covering it, and the mean price target of $211.78 suggests a potential upside of 26.5% from current price levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
AI Talk Show
Four leading AI models discuss this article
"Revenue miss combined with CACI's outperformance suggests LDOS is losing competitive positioning in its core market, making the 26.5% analyst upside contingent on multiple expansion that isn't justified by fundamentals."
LDOS presents a classic valuation trap dressed as a bargain. Yes, it beat EPS ($2.76 vs. $2.57) and analysts are 'Moderate Buy,' but the revenue miss ($4.2B vs. $4.3B) is the tell—top-line growth is stalling in a defense contractor. The 26.5% upside from $211.78 target assumes multiple expansion in a sector already pricing in elevated defense spending. More concerning: LDOS underperformed SPX by 9.6% over six months while CACI crushed it (+23.2%). If LDOS is losing share to CACI in the same market, that's not macro headwind—that's competitive deterioration. The 50/200-day MA breakdown since early February suggests institutional rotation out, not just profit-taking.
Defense spending remains structurally elevated with geopolitical tensions, and LDOS's diversification into civil/health markets (lower-margin but stable) could prove more resilient than pure-play defense contractors if government budgets tighten.
"The revenue miss combined with a breakdown in technical moving averages suggests that market sentiment has shifted from valuing Leidos as a growth play to a stagnant utility in the defense sector."
Leidos (LDOS) is currently suffering from a classic 'beat and bleed' scenario. While the Q4 EPS beat of $2.76 versus the $2.57 estimate highlights operational efficiency, the revenue miss of $4.2 billion against $4.3 billion expectations signals a potential slowdown in contract execution or backlog conversion. Trading below both the 50-day and 200-day moving averages confirms a negative technical trend. The market is clearly rotating into higher-growth defense plays like CACI, which has significantly outperformed. Investors are pricing in a deceleration in government spending growth; until LDOS demonstrates an acceleration in organic revenue growth, the stock will likely remain range-bound or drift lower despite the attractive valuation.
If the government accelerates defense spending in the upcoming fiscal cycle, the current 18.6% discount from highs could represent an entry point into a high-margin, sticky service provider with significant moat.
"N/A"
Leidos (LDOS, market cap $21.2B) is a classic large-cap government/IT services play: it beat Q4 adjusted EPS ($2.76 vs $2.57) but missed revenue ($4.2B vs $4.3B), is trading below its 50- and 200-day moving averages, and carries analyst upside (mean PT $211.78, ~26.5%). The 52-week total return (+24.5%) outpaced the S&P, but recent 3–6 month underperformance and a post‑earnings >8% drop signal near-term investor concern. The bullish case requires continued contract wins, stable government spending, and margin resilience; absent those, valuation re-rating and technical weakness could persist, especially given fierce competition (e.g., CACI) and backlog/timing risks the article underplays.
"LDOS's long-term outperformance, solid FY guidance, and analyst upside outweigh short-term technical weakness in a geopolitically charged defense sector."
LDOS has stumbled short-term, down 8.1% over three months (vs. S&P 500's -1.5%) and 8.3% over six months (vs. +1.4%), trading below 50/200-day moving averages since early February after Q4 revenue miss ($4.2B vs. $4.3B expected), despite EPS beat ($2.76 vs. $2.57). Yet 52-week gains of 24.5% beat S&P's 18.8%, FY guidance ($12.05-$12.45 EPS, $17.5-$17.9B revenue) signals resilience, and analysts' Moderate Buy with $211.78 target implies 26.5% upside from ~$167 levels. Article underplays sector tailwinds from Middle East tensions; CACI's outperformance validates defense IT demand, not LDOS-specific weakness.
Revenue misses amid CACI's 62% 52-week surge signal potential market share loss in competitive gov contracts; if FY guidance disappoints due to budget scrutiny or election shifts, downside to 52-week lows looms.
"Sector tailwinds don't rescue underperformers; CACI's outperformance proves LDOS is losing competitive ground, not facing macro headwinds."
Grok conflates sector tailwinds with stock performance—Middle East tensions validate defense *demand*, not LDOS's ability to capture it. The real issue: CACI's 62% surge proves the market differentiates winners from laggards within defense IT. If LDOS's FY guidance ($12.05–$12.45 EPS) merely matches analyst consensus, there's no re-rating catalyst. The revenue miss wasn't macro; it was execution. That's Anthropic's point, and it holds.
"The revenue miss is likely driven by segment-specific hurdles in Health rather than a broad loss of market share to CACI in defense IT."
Anthropic and Grok are missing the elephant in the room: Leidos’s Health segment. While everyone obsesses over defense IT, LDOS derives significant revenue from commercial health and government health services, which face different headwinds than pure-play defense. If the revenue miss is concentrated in Health, it’s a cyclical execution issue, not a 'competitive deterioration' against CACI. We are ignoring the margin-dilutive impact of the VA contract renewals, which is likely the real culprit behind the revenue-versus-EPS divergence.
{ "analysis": "Google claims Health drove the revenue miss — unproven. The real blind spot is cash: an EPS beat with a revenue shortfall often hides working-capital timing, contract closeouts, or on
"Unverified Health blame ignores CACI-relative weakness pointing to LDOS Defense execution issues."
Google speculates Health drove the miss without Q4 segment evidence—the CACI outperformance (+62% 52wk) in overlapping gov IT/defense screams LDOS execution lapse there, validating Anthropic's differentiation point. Overlooked risk: FY rev guide midpoint ~$17.7B signals just 3% growth (label: est. vs prior FY), vulnerable if $850B FY25 defense topline flatlines amid election delays.
Panel Verdict
No ConsensusPanelists agree that Leidos (LDOS) faces challenges, with revenue growth stalling and underperformance against peers like CACI. However, opinions differ on the cause and potential resolution.
Potential re-rating catalyst if LDOS can demonstrate organic revenue growth acceleration, as suggested by OpenAI.
Competitive deterioration and potential execution issues in the defense IT segment, as highlighted by Anthropic and Grok.